PMID- 23681931
OWN - NLM
STAT- MEDLINE
DCOM- 20131230
LR  - 20200930
IS  - 1521-4095 (Electronic)
IS  - 0935-9648 (Linking)
VI  - 25
IP  - 23
DP  - 2013 Jun 18
TI  - In vivo bio-safety evaluations and diagnostic/therapeutic applications of 
      chemically designed mesoporous silica nanoparticles.
PG  - 3144-76
LID - 10.1002/adma.201205292 [doi]
AB  - The remarkable progress of nanotechnology and its application in biomedicine have 
      greatly expanded the ranges and types of biomaterials from traditional organic 
      material-based nanoparticles (NPs) to inorganic biomaterials or organic/inorganic 
      hybrid nanocomposites due to the unprecedented advantages of the engineered 
      inorganic material-based NPs. Colloidal mesoporous silica NPs (MSNs), one of the 
      most representative and well-established inorganic materials, have been promoted 
      into biology and medicine, and shifted from extensive in vitro research towards 
      preliminary in vivo assays in small-animal disease models. In this comprehensive 
      review, the recent progresses in chemical design and engineering of MSNs-based 
      biomaterials for in vivo biomedical applications has been detailed and 
      overviewed. Due to the intrinsic structural characteristics of elaborately 
      designed MSNs such as large surface area, high pore volume and easy chemical 
      functionalization, they have been extensively investigated for therapeutic, 
      diagnostic and theranostic (concurrent diagnosis and therapy) purposes, 
      especially in oncology. Systematic in vivo bio-safety evaluations of MSNs have 
      revealed the evidences that the in vivo bio-behaviors of MSNs are strongly 
      related to their preparation prodecures, particle sizes, geometries, surface 
      chemistries, dosing parameters and even administration routes. In vivo 
      pharmacokinetics and pharmacodynamics further demonstrated the effectiveness of 
      MSNs as the passively and/or actively targeted drug delivery systems (DDSs) for 
      cancer chemotherapy. Especially, the advance of nano-synthetic chemistry enables 
      the production of composite MSNs for advanced in vivo therapeutic purposes such 
      as gene delivery, stimuli-responsive drug release, photothermal therapy, 
      photodynamic therapy, ultrasound therapy, or anti-bacteria in tissue engineering, 
      or as the contrast agents for biological and diagnostic imaging. Additionally, 
      the critical issues and potential challenges related to the chemical 
      design/synthesis of MSNs-based "magic bullet" by advanced nano-synthetic 
      chemistry and in vivo evaluation have been discussed to highlight the issues 
      scientists face in promoting the translation of MSNs-based DDSs into clinical 
      trials.
CI  - Copyright (c) 2013 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
FAU - Chen, Yu
AU  - Chen Y
AD  - State Key Laboratory of High Performance, Ceramics and Superfine Microstructures, 
      Shanghai Institute of Ceramics, Chinese Academy of Sciences, 1295 Ding-Xi Road, 
      Shanghai 200050, P. R. China.
FAU - Chen, Hangrong
AU  - Chen H
FAU - Shi, Jianlin
AU  - Shi J
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20130517
PL  - Germany
TA  - Adv Mater
JT  - Advanced materials (Deerfield Beach, Fla.)
JID - 9885358
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Biocompatible Materials)
RN  - 0 (Contrast Media)
RN  - 0 (Drug Carriers)
RN  - 0 (Lipid Bilayers)
RN  - 0 (RNA, Small Interfering)
RN  - 7631-86-9 (Silicon Dioxide)
SB  - IM
MH  - Animals
MH  - Antineoplastic Agents/administration & dosage
MH  - Biocompatible Materials/*chemistry
MH  - Contrast Media
MH  - Drug Carriers/chemistry
MH  - Humans
MH  - Lipid Bilayers/metabolism
MH  - Nanoparticles/*chemistry
MH  - Neoplasms/diagnosis/diagnostic imaging/drug therapy
MH  - Porosity
MH  - RNA, Small Interfering/administration & dosage
MH  - Silicon Dioxide/*chemistry
MH  - Tissue Engineering
MH  - Ultrasonography
EDAT- 2013/05/18 06:00
MHDA- 2014/01/01 06:00
CRDT- 2013/05/18 06:00
PHST- 2012/12/24 00:00 [received]
PHST- 2013/02/27 00:00 [revised]
PHST- 2013/05/18 06:00 [entrez]
PHST- 2013/05/18 06:00 [pubmed]
PHST- 2014/01/01 06:00 [medline]
AID - 10.1002/adma.201205292 [doi]
PST - ppublish
SO  - Adv Mater. 2013 Jun 18;25(23):3144-76. doi: 10.1002/adma.201205292. Epub 2013 May 
      17.